8-K: vTv Therapeutics Expands Global License Agreement with Newsoara Biopharma

vTv Therapeutics has amended its licensing agreement with Newsoara Biopharma, potentially securing up to $96 million in upfront and milestone payments, plus royalties.

Summary

• vTv Therapeutics has entered into a Second Amendment to its License Agreement with Newsoara Biopharma, expanding the original license to a global one.
• Newsoara will pay an upfront fee of $20 million within one year of the agreement date, or the amendment will be void.
• The agreement also includes up to $41 million in development milestones and $35 million in sales-related milestones.
• vTv Therapeutics will receive royalties in the mid to upper single digits based on sales volumes.

Sentiment

Score: 8

Explanation: The agreement is a positive development for vTv Therapeutics, with significant potential revenue and market expansion. However, the upfront payment is not guaranteed, and milestone payments are contingent on future success.

Positives

• The expansion of the license to a global agreement significantly increases the potential market for vTv Therapeutics' product.
• The upfront payment of $20 million provides immediate capital to vTv Therapeutics.
• The potential for $76 million in milestone payments offers significant future revenue opportunities.
• The royalty structure provides ongoing revenue based on sales performance.

Negatives

• The $20 million upfront payment is not guaranteed, as Newsoara has up to one year to make the payment.
• The milestone payments are contingent on the successful development and commercialization of the product.

Risks

• There is a risk that Newsoara may not pay the $20 million upfront fee within the one-year timeframe, rendering the amendment null and void.
• The development and sales milestones are subject to the success of the product, which is not guaranteed.
• The royalty payments are dependent on sales volumes, which may fluctuate.

Future Outlook

The agreement provides a potential for significant revenue for vTv Therapeutics through upfront payments, milestone payments, and royalties, contingent on Newsoara's payment and the success of the product.

Management Comments

• Paul J. Sekhri, Chairman, President, and Chief Executive Officer, signed the report on behalf of vTv Therapeutics Inc.

Industry Context

This agreement is a positive development for vTv Therapeutics, as it expands their market reach and provides potential revenue streams. Such licensing agreements are common in the pharmaceutical industry, allowing companies to leverage their intellectual property and development capabilities.

Comparison to Industry Standards

• Licensing agreements in the pharmaceutical industry often include upfront payments, milestone payments, and royalties, similar to this agreement.
• The specific terms of the agreement, such as the size of the upfront payment and the royalty rates, are within the typical range for such deals.
• Comparable companies often seek similar partnerships to expand their market reach and share development costs.

Stakeholder Impact

• Shareholders may view this agreement positively due to the potential for increased revenue and market expansion.
• Employees may benefit from the company's improved financial position and growth prospects.
• Customers may benefit from the potential development of new products.

Next Steps

• Newsoara has up to one year to pay the $20 million upfront fee.
• vTv Therapeutics intends to file the Second Amendment with the SEC as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

Key Dates

Keywords

licensing agreement, global license, milestone payments, royalties, pharmaceutical, biopharma, vTv Therapeutics, Newsoara Biopharma